Nxera’s Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

Core Insights - Nxera Pharma's partner, Cancer Research UK, presented data from the completed Phase 1 part of the Phase 1/2a clinical trial of the immunotherapy drug HTL0039732 at the ESMO 2025 Congress [1][2] - The trial evaluates HTL0039732 as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors resistant to standard therapy [2][4] Clinical Trial Details - The Phase 1 trial involved 13 patients receiving HTL0039732 as a monotherapy and 22 patients receiving it in combination with atezolizumab [2] - The Phase 2a trial will expand to four cohorts: MSS CRC, gastric or gastroesophageal junction adenocarcinoma, clear cell renal cell carcinoma, and metastatic castration-resistant prostate cancer [2] - The first patient in the Phase 2a trial was dosed in September 2025 [2] Safety and Efficacy Results - HTL0039732 demonstrated a robust safety profile with no grade 4/5 treatment-related adverse events and no dose-limiting toxicities [5] - Grade 3 treatment-related adverse events occurred in 14% of combination patients, aligning with established data for atezolizumab monotherapy [5] - Confirmed partial responses were observed in two patients, one with metastatic renal cell cancer and another with MSS-CRC, indicating early efficacy [5] Future Development - The recommended Phase 2 dose for cohort expansion studies is set at 160mg QD in combination with atezolizumab [5] - The trial's data suggests HTL0039732 has the potential to be best-in-class among drugs with the same mechanism of action [6] Company Overview - Nxera Pharma is a biopharma company focused on developing specialty medicines for unmet medical needs [9] - The company utilizes its NxWave™ discovery platform to advance a pipeline of over 30 active programs across various therapeutic areas [10] - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [11]